Company Files for Approval of New Pustular Psoriasis Rx

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/company-files-approval-biologic-treating-generalized-2026a100060x?src=rss

Author :

Publish date : 2026-02-26 04:29:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Company Files for Approval of New Pustular Psoriasis Rx

Low Coronary Plaque Burden May Not Equal Low Risk in Women

Peer Navigator Program in EDs Fails to Reduce Opioid Events

Related Posts

Store Peanut Products Effective for Desensitization in Kids?

Tenecteplase May Help Stroke Recovery Past 4.5-Hour Window

Racism and staffing issues factors in ‘failing’ maternity care, report finds

Nearly a Third of US Youth Have Prediabetes or Diabetes

Peer Navigator Program in EDs Fails to Reduce Opioid Events

Low Coronary Plaque Burden May Not Equal Low Risk in Women

Store Peanut Products Effective for Desensitization in Kids?

Tenecteplase May Help Stroke Recovery Past 4.5-Hour Window

Racism and staffing issues factors in ‘failing’ maternity care, report finds

Nearly a Third of US Youth Have Prediabetes or Diabetes

Peer Navigator Program in EDs Fails to Reduce Opioid Events

Company Files for Approval of New Pustular Psoriasis Rx

Low Coronary Plaque Burden May Not Equal Low Risk in Women

ACOG Withdraws From ACIP, Citing Scientific Integrity Concerns

Categories

Archives